Journal
DRUG AND ALCOHOL DEPENDENCE
Volume 121, Issue 1-2, Pages 163-166Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.drugalcdep.2011.08.025
Keywords
Cocaine; Treatment; Pharmacotherapy; Contingency management
Categories
Funding
- NIH [P60-DA-005186, P50-DA-12756]
Ask authors/readers for more resources
Background: Cocaine use, abuse and dependence remains a pressing public health problem. Based on its mechanism of action, varenicline, an alpha4beta2 partial agonist seemed to be a likely candidate for treating cocaine dependence. Methods: Cocaine dependent participants (n=37) were enrolled in a 9-week double-blind placebo controlled clinical trial. Varenicline was titrated up to a target dose of 1 mg BID during the first week of medication. Results: Varenicline was associated with lower odds of cocaine use than placebo (OR=2.02, p=0.08), as measured by thrice-weekly urinalysis results. Compared to placebo-treated participants, varenicline treated participants had significantly decreased rates of cocaine reward, as measured by the Multiple Choice Procedure (MCP) (p=0.02). Conclusions: Varenicline appears to decrease cocaine use and reward, suggesting that further investigation of varenicline may be warranted. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available